Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29


March 20, 2014 5:00 pm ET

Merck (NYSE:MRK), known as MSD outside the United States and Canada,
will hold its first-quarter 2014 sales and earnings conference call with
institutional investors and analysts at 8:00 a.m. EDT on Tuesday, April
29. During the call, company executives will provide an overview of
Merck’s performance for the quarter.

Investors, journalists and the general public may access a live audio
webcast of the call on Merck’s website at
Software needed to listen to the webcast is available on Merck’s website
and should be downloaded prior to the beginning of the webcast. A replay
of the webcast will be available at approximately 11:00 a.m. EDT on
April 29 and will remain on the website for 12 months. The quarter’s
sales and earnings news release and supplemental financial disclosures
also will be available in the Newsroom and Investor sections of the
company’s website at

Institutional investors and analysts can participate in the call by
dialing (706) 758-9927 or (877) 381-5782 and using ID code number
17424702. Members of the media are invited to monitor the call by
dialing (706) 758-9928 or (800) 399-7917 and using ID code number
17424702. Journalists who wish to ask questions are requested to contact
a member of Merck’s Media Relations team at the conclusion of the call.

About Merck

Today’s Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies, and
consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships. For
more information, visit
and connect with us on Twitter,
and YouTube.

Merck Forward-Looking Statement

This news release includes “forward-looking statements” within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of Merck’s management and are
subject to significant risks and uncertainties. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; Merck’s ability to accurately
predict future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign risk;
dependence on the effectiveness of Merck’s patents and other protections
for innovative products; and the exposure to litigation, including
patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in Merck’s 2013 Annual Report on Form 10-K and the company’s other
filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (

Kelley Dougherty, 267-305-3552
Steven Cragle, 908-423-3461
Carol Ferguson, 908-423-4465
Joe Romanelli, 908-423-5185

Unsubscribe from email alerts